Compare Bank of New York Mellon Corp (BNY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Viatris Inc — how do they compare? Bank of New York Mellon Corp trades at $162.88 (market cap $108.78B), while Viatris Inc trades at $16.3 (market cap $18.69B). The key difference: Bank of New York Mellon Corp is far larger — about 5.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| BNY | VTRS | |
|---|---|---|
Market Cap | $108.78B | $18.69B |
Sector | Financials | Health |
52-Week High | $162.35 | $17.86 |
52-Week Low | $101.00 | $9.49 |
Dividend Yield | 1.38% | 2.95% |
Enterprise Value | — | $30.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY stock trades at $159.44, up 1.14% on the day, near the analyst consensus price target of $170.36. The stock shows a bullish technical trend with strong moving average signals, and fundamentals are robust with consistent earnings beats, revenue growth to $19.76B in 2025, and a net income margin of 29.96%. Recent news highlights strategic moves in digital asset infrastructure and a dividend declaration.
The outlook for BNY is positive, supported by earnings momentum and digital innovation, but risks include high investing cash outflows and interest expenses. Analyst sentiment is mixed with a slight hold bias, yet institutional upgrades and a strong ROE of 15.34% offer upside potential amid market volatility.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
